Sei Investments Co. reduced its position in Zimmer Biomet Holdings Inc. (NYSE:ZBH) by 0.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 129,786 shares of the company’s stock after selling 1,240 shares during the period. Sei Investments Co. owned about 0.06% of Zimmer Biomet Holdings worth $16,874,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the company. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Zimmer Biomet Holdings by 1.1% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,134 shares of the company’s stock worth $975,000 after buying an additional 101 shares in the last quarter. First Republic Investment Management Inc. boosted its stake in shares of Zimmer Biomet Holdings by 1.2% in the first quarter. First Republic Investment Management Inc. now owns 32,070 shares of the company’s stock valued at $3,420,000 after buying an additional 384 shares in the last quarter. Stock Yards Bank & Trust Co. boosted its stake in shares of Zimmer Biomet Holdings by 2.9% in the second quarter. Stock Yards Bank & Trust Co. now owns 66,654 shares of the company’s stock valued at $8,024,000 after buying an additional 1,890 shares in the last quarter. Howland Capital Management LLC boosted its stake in shares of Zimmer Biomet Holdings by 0.7% in the second quarter. Howland Capital Management LLC now owns 6,985 shares of the company’s stock valued at $841,000 after buying an additional 50 shares in the last quarter. Finally, Raymond James Trust N.A. boosted its stake in shares of Zimmer Biomet Holdings by 2.2% in the second quarter. Raymond James Trust N.A. now owns 9,870 shares of the company’s stock valued at $1,188,000 after buying an additional 217 shares in the last quarter. 85.05% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) traded down 0.488% during trading on Wednesday, hitting $102.895. 488,526 shares of the stock traded hands. The stock has a 50 day moving average price of $112.33 and a 200-day moving average price of $121.63. Zimmer Biomet Holdings Inc. has a 1-year low of $88.27 and a 1-year high of $133.21. The stock has a market cap of $20.61 billion, a price-to-earnings ratio of 57.612 and a beta of 1.28.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Monday, October 31st. The company reported $1.79 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.79. Zimmer Biomet Holdings had a return on equity of 16.48% and a net margin of 3.46%. The firm earned $1.83 billion during the quarter, compared to analyst estimates of $950.20 million. During the same quarter last year, the firm earned $1.64 EPS. Zimmer Biomet Holdings’s quarterly revenue was up 4.0% on a year-over-year basis. Equities analysts forecast that Zimmer Biomet Holdings Inc. will post $7.92 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Zimmer Biomet Holdings Inc. (ZBH) Shares Sold by Sei Investments Co.” was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another site, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2016/11/30/zimmer-biomet-holdings-inc-zbh-shares-sold-by-sei-investments-co.html.

Several equities research analysts have recently commented on ZBH shares. RBC Capital Markets reiterated an “outperform” rating and set a $130.00 price target (down previously from $143.00) on shares of Zimmer Biomet Holdings in a research report on Tuesday, November 1st. Barclays PLC boosted their price objective on shares of Zimmer Biomet Holdings from $140.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, August 23rd. Canaccord Genuity restated a “buy” rating and set a $130.00 price objective (down previously from $150.00) on shares of Zimmer Biomet Holdings in a report on Monday, October 31st. Argus restated a “buy” rating and set a $140.00 price objective on shares of Zimmer Biomet Holdings in a report on Thursday, September 22nd. Finally, Northcoast Research cut shares of Zimmer Biomet Holdings from a “buy” rating to a “neutral” rating in a report on Tuesday, November 8th. Four investment analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $131.15.

In other news, insider Daniel E. Williamson sold 2,716 shares of Zimmer Biomet Holdings stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $129.96, for a total value of $352,971.36. Following the completion of the transaction, the insider now owns 2,000 shares in the company, valued at approximately $259,920. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 1.22% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.